Пт, 04/17/2015 - 12:37 — admin

Welcome to this edition of EMJ’s nephrology newsletter. We are now in a new season filled with exciting developments and news from the field; included is a report on the fascinating breakthrough in the use of nanotechnology for kidney disease diagnosis and treatment, and a study suggesting that ingesting higher amounts of lycopene could reduce the risk of developing kidney cancer in postmenopausal women. Additionally, in this newsletter is a rundown of the most exciting upcoming events, including the hotly anticipated 33rd Vicenza Course on Critical Care Nephrology, one of the most comprehensive courses covering research and practice. The EMJ nephrology newsletter provides just a hint of the year to come. With more events, studies, and reports ahead, 2015 has the makings of a great year, so make sure you subscribe to our EMJ Nephrology eJournal to keep up to date with all of the latest developments.
 
Articles
 
M Niemczyk
 
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder affecting 1 in 1,000 people and is responsible for 10% of cases of end-stage renal disease. Apart from renal manifestations, changes in other organs may be present, including arterial hypertension, intracranial aneurysms, liver cysts, and others. Pain is a common complaint in ADPKD, afflicting as many as two-thirds of patients. It begins relatively early in the course of the disease, and may be associated with polycystic kidneys, extrarenal manifestations of the disease, or may be of the origin which is unspecific for ADPKD. The aim of the paper is to review the subject of pain in ADPKD patients, with its possible sources, diagnostics, and management.
 

S Samoni et al.
Renal denervation (RD) is a new clinical procedure which aims to treat resistant hypertensive patients. As with every new technology introduced into the clinical setting, many aspects were not explored sufficiently in order to be implemented into routine clinical practice. Advances in clinical technology require different steps of development, which start from preliminary in vitro experiments and finally arrive in the market, available for physicians when they have been proven to produce benefits for patients. Each stage usually takes many years before acquiring consensus from specialists involved in specific fields. In our opinion, this is a long and blind way and is a disadvantage to patients who need rapid, specific, and effective treatments. Otherwise, a multidisciplinary approach can provide the right evaluation of RD position and its potential for clinical application and research development. Therefore, we decided to draw a well-structured literature review from different specialists’ points of view in order to cover the subject in a translational manner. We reported animal models and experimental trials, in chronological order, and their evidences which have created the basis for human research. Technologies and devices were compared to underlined advantages and disadvantages. An update of clinical data was considered to define clinical needs in order to build focused trials. Furthermore, we evaluate the feasibility of routine RD clinical use by means of an economic analysis. Finally, we tried to settle the main unresolved questions and then assessed future RD perspectives, including non-hypertension indications.

 
 

News Updates

 

 

 

Taking Lycopene Everyday Could Help Keep Kidney Cancer at Bay

“Lycopene from food sources has also been associated with decreased risk of breast and prostate cancers, and a diet high in vegetables and fruits is generally well accepted for promoting good health.”
 

Revamped Pregnancy Tester Could Detect Kidney Disease in Millions

 

“Using an old technology like a pregnancy tester and combining it with nanotechnology, you have a device which could not only diagnose the million people in the UK who are unaware they have kidney disease, but also help doctors effectively monitor those undergoing treatment.”

 

What’s Happening in EMJ: Nephrology
 
The subsequent long-awaited EMJ Nephrology 3.1 eJournal will be published in July 2015 and the EMJ team are eagerly awaiting the opening of the ERA-EDTA Congress, to be held in the grand city of London. So join us as we descend on the British capital for a memorable congress, which will attract many international specialists who will showcase the latest updates in the field. You can follow all of the recent news on our range of social media channels, including Facebook, LinkedIn, and Twitter: @EMJNephrology.

European Medical Journal 

 

Head Office – The MedBIC, Anglia Ruskin University, Alan Cherry Drive, Chelmsford, Essex, CM1 1SQ

Sales Office - Coppergate House, 16 Brune Street, London, E1 7NJ 

 

Switchboard: +44 (0) 1245 334450 

 

 

Registration No: 08198092. The information contained in this message is confidential and maybe legally privileged. It is intended for the addresses(s) only. Any unauthorised use, dissemination of the information, or unauthorised copying/forwarding of this message is prohibited. If you are not the intended addressee, please notify the sender immediately by return email and delete this message. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorised to state them.